Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tecadenoson · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol low dose infusion |
| Cohort B | EXPERIMENTAL | Period 1: 150 mcg, i.v. bolus. Period 2: 150 mcg, i.v. bolus + esmolol low dose infusion |
| Cohort C | EXPERIMENTAL | Period 1: 300 mcg, i.v. bolus. Period 2: 300 mcg, i.v. bolus + esmolol low dose infusion |
| Cohort D | EXPERIMENTAL | Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol high dose infusion |
| Cohort E | EXPERIMENTAL | Period 1: 150 or 300 mcg, i.v. bolus. Period 2: 150 or 300 mcg, i.v. bolus + esmolol high dose infusion |
| Name | Type | Description |
|---|---|---|
| Tecadenoson | DRUG | Tecadenoson administered intravenously (i.v.) |
| Esmolol | DRUG | Esmolol low dose infusion according to manufacturer's instructions |
Inclusion Criteria: * Have a diagnosis of atrial fibrillation in need of treatment for rate control * Be able and willing to abstain from any antiarrhythmics, including atrioventricular (AV) nodal blocking agents (except for esmolol per protocol), from no later than 8:00 p.m. on the day prior to do...
Tecadenoson is an investigational small molecule being studied for the treatment of atrial fibrillation, a condition characterized by an irregular and often rapid heart rate. It is being developed by Gilead Sciences, Inc. (GILD) and is currently in Phase 2 clinical development.
Tecadenoson is a small molecule that acts on the cardiovascular system. It is being investigated for its potential to treat atrial fibrillation by affecting heart rhythm. The specific molecular target of Tecadenoson has not been disclosed in the available information.
Tecadenoson is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The drug is currently in Phase 2 clinical development for the treatment of atrial fibrillation.
Tecadenoson is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial of Tecadenoson for atrial fibrillation has been completed.
Tecadenoson has been studied in a completed Phase 2 clinical trial with the identifier NCT00713401, titled "Safety Study of Tecadenoson to Treat Atrial Fibrillation." The trial enrolled 21 participants in the United States and evaluated the safety of the drug in patients with atrial fibrillation.
Tecadenoson is a distinct investigational drug developed by Gilead Sciences. It is not known to be the same as any other marketed medication. It is being studied specifically for its potential use in treating atrial fibrillation.